Teva Pharma (TEVA) Tops Q2 EPS by 12c; Boosts FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Teva Reports Strong Second Quarter 2015 Results and Raises Guidance for Full-Year 2015
July 30, 2015 7:00 AM EDTRevenues of $5.0 billion, in line with the second quarter of 2014. Non-GAAP operating income of $1.6 billion, an increase of 16% compared to the second quarter of 2014. GAAP operating income of $662 million, down 28%. Non-GAAP net income of $1.2 billion, up 15% compared to the second quarter of 2014. GAAP net income of $539 million, a decrease of 28%. Quarterly non-GAAP EPS of $1.43, an increase of 14% compared to the second quarter of 2014. GAAP diluted EPS of $0.63, a decrease of 28%. Strong cash flow from operations of $1.5 billion, an increase of 41%... More
